{
    "type": "ETF",
    "ucits": true,
    "replication_method": "synthetic",
    "swaps": true,
    "derivatives": true,
    "leverage": false,
    "inverse": false,
    "complex_factors": [
        "Synthetic replication via total return swap",
        "Counterparty risk exposure",
        "Emerging markets underlying index",
        "Use of derivatives as inherent strategy element"
    ],
    "classification": "complex",
    "supporting_data": "The UBS MSCI Emerging Markets SF UCITS ETF uses synthetic replication through a fully funded total return swap with UBS AG as the counterparty, as confirmed by the KIID, PRIIPs KID, and the monthly factsheet. The fund invests in financial derivative instruments (FDIs) with UBS as counterparty, swapping the index performance for the performance of securities held by the fund. This swap structure inherently exposes investors to counterparty risk, explicitly highlighted in the risk disclosures. The replication method is not physical but synthetic, relying on derivative contracts rather than direct ownership of the underlying securities. There is no leverage or inverse exposure, and the fund is UCITS compliant. The risk profile is medium to high (risk category 5 in KIID, 4 in PRIIPs KID), reflecting volatility and counterparty risk. The underlying index is a broad emerging markets equity index, which adds complexity due to market illiquidity and political risks typical of emerging markets. Costs are straightforward with a low TER and no performance fees, but swap fees and derivative costs are implicit. The PRIIPs KID does not carry a specific comprehension warning but confirms the use of swaps and counterparty risk. Given the synthetic replication via total return swaps and the associated counterparty risk, the fund meets MiFID II criteria for classification as a complex financial instrument despite the absence of leverage or capital protection features."
}